FDA sanctions Teva Pharmaceutical’s TRISENOX for Acute Promyelocytic Leukemia treatment

U.S FDA approves Teva Pharmaceutical’s TRISENOX i.e. Arsenic trioxide injection amalgamated with  tretinoin  in the therapy of adults diagnosed with low -risk acute promyelocytic leukemia (APL)  signifying t(15;17) translocation or PML/RAR-alpha gene expression.

Paul Rittman, Senior Vice President and General Manager, Teva Oncology. “This label expansion represents an important benefit as TRISENOX is now an FDA-approved first line treatment option for patients with acute promyelocytic leukemia.”

The new therapy is in accordance with the guidelines laid down by the National Comprehensive Cancer Network (NCCN).

There are certain contraindications in patients who are hypersensitive to arsenic. TRISENOX imparts certain important safety information with regards to differentiation between syndrome and Cardiac conduction abnormalities.